Trial-by-gene · RET

Active trials enrolling RET-altered cancers

Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.

RET-altered cancer trials focus on (1) post-selpercatinib / pralsetinib resistance, particularly solvent-front G810 mutations, (2) next-generation pan-RET inhibitors covering G810R/S/C, and (3) RET tumor-agnostic expansions beyond NSCLC and thyroid.

See the RET cheat sheet.

Browse the live listing

Search ClinicalTrials.gov for actively recruiting trials with RET-targeted interventions across NSCLC, MTC, and other solid tumors.

Open ClinicalTrials.gov listing

Source: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.

Representative trial phases and designs

Phase I/II, post-selpercatinib

Next-gen pan-RET inhibitors after solvent-front mutation (LOXO-260 and others).

Phase II, tumor-agnostic

Selpercatinib expansion across non-NSCLC non-thyroid RET fusion-positive solid tumors.

Frequently asked questions

Are RET-mutant MTC trials different from RET-fusion NSCLC trials?
Yes. MTC trials enroll on RET point mutations (M918T, others) common in sporadic and MEN2-related MTC. NSCLC trials enroll on RET fusions (KIF5B-RET, CCDC6-RET).

Related